`
`UNITED STATES DISTRICT COURT
`NORTHERN DISTRICT OF ILLINOIS
`
`TRACY HALL, individually and on behalf of all
`others similarly situated,
`
` Plaintiff,
`
`vs.
`
`WALGREENS BOOTS ALLIANCE, INC. and
`WALGREEN CO.,
`
` Defendants
`
`
`
`
`
`Case No. 1:22-cv-00024
`
`JURY TRIAL DEMANDED
`
`
`
`
`
`
`CLASS ACTION COMPLAINT
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`i
`
`
`
`
`
`
`
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 2 of 19 PageID #:2
`
`Table of Contents
`
`I.
`II.
`III.
`IV.
`
`V.
`VI.
`VII.
`
`B.
`C.
`
`Introduction. ........................................................................................................................ 1
`Parties. ................................................................................................................................. 1
`Jurisdiction and Venue. ....................................................................................................... 2
`Facts. ................................................................................................................................... 2
`Defendants make, market, and sell Walgreens products prominently
`A.
`labeled “Non-Drowsy.”........................................................................................... 2
`The Non-Drowsy Walgreens Products cause drowsiness. ...................................... 4
`Defendants’ Non-Drowsy representations are misleading to reasonable
`consumers. .............................................................................................................. 6
`Plaintiff was misled by Defendants’ misrepresentations ........................................ 8
`D.
`Class Action Allegations......................................................................................... 9
`E.
`Claims. .............................................................................................................................. 11
`Jury Demand. .................................................................................................................... 16
`Prayer for Relief. ............................................................................................................... 16
`
`
`
`ii
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 3 of 19 PageID #:3
`
`I.
`
`Introduction.
`
`1.
`
`Defendants make, sell, and market “Walgreens” over-the-counter cough
`
`medicine, including generic Walgreens versions of brands like Robitussin and DayQuil. Like the
`
`branded versions, many of these medicines contain the active ingredient Dextromethorphan
`
`Hydrobromide (“DXM”). Many such Walgreens products state prominently on the front of their
`
`label that they are “Non-Drowsy.” 1
`
`2.
`
`By prominently labeling these products as “Non-Drowsy,” Defendants led
`
`Plaintiff and other reasonable consumers to believe that the Non-Drowsy Walgreens Products do
`
`not cause drowsiness, and that drowsiness is not a side effect of those products. But the truth is
`
`that products containing DXM—and thus the Non-Drowsy Walgreens Products—do cause
`
`drowsiness, and that drowsiness is a common side effect of DXM.
`
`3.
`
`In this way, Defendants misled Plaintiff and other reasonable consumers about the
`
`effects of the Non-Drowsy Walgreens Products.
`
`4.
`
`Defendants’ misrepresentations allowed them to overcharge Plaintiff and other
`
`consumers for the Non-Drowsy Walgreens Products.
`
`II.
`
`Parties.
`
`5.
`
`Plaintiff Tracy Hall is a citizen of Washington (domiciled in Blaine, Washington).
`
`The proposed class includes citizens of every state within the United States.
`
`6.
`
`Defendant Walgreens Boots Alliance, Inc. is a citizen of Illinois and Delaware.
`
`Its principal place of business is at 108 Wilmot Road, Deerfield, Illinois, 60015. It is
`
`incorporated in Delaware.
`
`
`1 Throughout this Complaint, Walgreens products containing DXM that state on their
`label that they are “Non-Drowsy” are called “Non-Drowsy Walgreens Products.”
`
`1
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 4 of 19 PageID #:4
`
`7.
`
`Defendant Walgreen Co. is a citizen of Illinois. Its principal place of business is
`
`at 108 Wilmot Road, Deerfield, IL 60015. It is incorporated in Illinois.
`
`III.
`
`Jurisdiction and Venue.
`
`8.
`
`This Court has subject matter jurisdiction under 28 U.S.C. § 1332(d)(2). The
`
`amount in controversy exceeds the sum or value of $5,000,000, exclusive of interest and costs,
`
`and the matter is a class action in which one or more members of the proposed class are citizens
`
`of a state different from the Defendants.
`
`9.
`
`The Court has personal jurisdiction over Defendants because Defendants’
`
`principal place of business is in Illinois.
`
`10.
`
`Venue is proper under 28 U.S.C. § 1391(b)(1) and 28 U.S.C. § 1391(d) because
`
`Defendants would be subject to personal jurisdiction in this District if this District were a
`
`separate state, given that Defendants’ principal place of business is in this district.
`
`IV.
`
`Facts.
`
`A.
`
`Defendants make, market, and sell Walgreens products prominently
`labeled “Non-Drowsy.”
`
`11. Walgreens Boots Alliance makes, markets and sells the Non-Drowsy Walgreens
`
`Products and is therefore liable for them. In its 10-K, Walgreens Boots Alliance states: “The
`
`Company provides customers with convenient, omni-channel access through its portfolio of
`
`retail and business brands, which includes Walgreens [brand] . . . . The Company’s global brands
`
`portfolio is enhanced by its in-house product research and development capabilities . . .
`
`Additionally, through its strategic partnerships, the Company will be able to dramatically
`
`enhance Walgreens Boots Alliance’s marketing effectiveness.”
`
`12.
`
`In addition, or in the alternative, Walgreen Co. makes, markets and sells the Non-
`
`Drowsy Walgreens Products and is therefore liable for them. According to Walgreen Co.’s
`
`2
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 5 of 19 PageID #:5
`
`representations in a recent lawsuit, Walgreen Co. is a wholly-owned subsidiary of Walgreens
`
`Boots Alliance that “owns and operates . . . licensed pharmacy locations.” Mot. to Dismiss, J.R.
`
`v. Walgreens Boots Alliance, Inc., No. 2:19-cv-00446-DCN, Dkt. 117 at 6 (October 18, 2019).
`
`13.
`
`The front label of each Non-Drowsy Walgreens Product prominently states that
`
`the product is “Non-Drowsy.” For example:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 6 of 19 PageID #:6
`
`
`
`
`
`14.
`
`Products.
`
`These representations are materially the same across Non-Drowsy Walgreens
`
`
`
`15.
`
`The Non-Drowsy Walgreens Products do not disclose anywhere on their
`
`packaging that they do or can cause drowsiness, or that drowsiness is a side effect.
`
`16.
`
`Based on the prominent “Non-Drowsy” label included on the face of each
`
`product, a reasonable consumer would believe that the products do not cause drowsiness, and
`
`that drowsiness is not a side-effect of the products.
`
`17.
`
`Defendants labeled the products this way because they intended consumers to rely
`
`on the labels and to believe that the products would not cause drowsiness, so that consumers
`
`would buy more products or pay more for them.
`
`B.
`
`18.
`
`The Non-Drowsy Walgreens Products cause drowsiness.
`
`In truth, products containing DXM—like the Non-Drowsy Walgreens Products—
`
`do cause drowsiness, and drowsiness is a documented side effect of DXM. 2
`
`
`2 Dextromethorphan: MedlinePlus Drug Information, NIH National Library of Medicine,
`https://medlineplus.gov/druginfo/meds/a682492.html (listing drowsiness as a side effect)
`
`4
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 7 of 19 PageID #:7
`
`19.
`
`In fact, drowsiness is a common side effect at the recommended dosages. For
`
`example, one study found that “[s]omnolence is a common side effect of centrally acting
`
`antitussive drugs” like dextromethorphan, and that 10.4% of users of products containing
`
`dextromethorphan develop drowsiness within three days of starting treatment with DXM cough
`
`medicine. 3, 4 The “cases of intense somnolence” were “related only to dextromethorphan” and
`
`not to the other drug studied. And patients in this clinical study were given an even smaller
`
`dosage of DXM (15 mg three times a day) than the recommended dose found in many Walgreens
`
`products. 5
`
`20.
`
`The FDA’s adverse event report database confirms that “sedation” is one of the
`
`most frequently-cited side effects of dextromethorphan-containing products. 6
`
`21.
`
`For this reason, the Federal Aviation Administration prohibits pilots from flying
`
`after ingesting medicines that contain “dextromethorphan”: 7
`
`
`3 E. Catena and L. Daffonchio, “Efficacy and Tolerability of Levodropropizine in Adult Patients with
`Non-productive Cough, Comparison with Dextromethorphan,” 10 Pulmonary Pharmacology &
`Therapeutics 89-96 (1997).
`4 The study reports this side effect as “somnolence.” Somnolence means “the quality or state of being
`drowsy.” Merriam Webster Dictionary, https://www.merriam-webster.com/dictionary/somnolence
`5 For example: Wal-Tussin DM Liquid contains 20mg of DXM per 10ml of liquid cough syrup and the
`recommended dosage for adults and children 12 and over is 10ml every 4 hours.
`6 Sedation is associated with drowsiness. See IV/Monitored Sedation, American Society of
`Anesthesiologists, https://www.asahq.org/madeforthismoment/anesthesia-101/types-of-
`anesthesia/ivmonitored-sedation/ (even “minimal” sedation means that “you’ll feel drowsy”)
`7 https://www.faa.gov/licenses_certificates/medical_certification/media/OTCMedicationsforPilots.pdf
`
`5
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 8 of 19 PageID #:8
`
`C.
`
`Defendants’ Non-Drowsy representations are misleading to reasonable
`consumers.
`
`22.
`
`The Food and Drug Administration prohibits drug labeling that is “false or
`
`misleading.” 21 C.F.R. § 201.6. It is misleading to label a product “Non-Drowsy” when it does
`
`cause drowsiness, or if drowsiness is a known side effect of one of its active ingredients.
`
`23.
`
`Based on the fact that Defendants labeled the Non-Drowsy Walgreens Products as
`
`“Non-Drowsy,” a reasonable consumer would expect that those products do not cause
`
`drowsiness. Similarly, a reasonable consumer would expect that drowsiness is not a side effect
`
`of the products (much less a common side effect). Indeed, according to Consumer Reports,
`
`“‘Non-drowsy’ is code for antihistamines and other medications that don’t make you sleepy.” 8
`
`This is the plain meaning of “non-drowsy,” which means “not causing or accompanied by
`
`drowsiness.” 9
`
`24. Walgreens’ labeling does not contain any language that a reasonable consumer
`
`would understand to qualify these representations, or that would otherwise put a reasonable
`
`consumer on notice of the fact that the Non-Drowsy Walgreens Products actually cause
`
`drowsiness.
`
`25.
`
`Unlike Defendants, some other drug makers do not falsely claim that DXM-
`
`products are non-drowsy. For example, DXM is an active ingredient in Mucinex DM, sold by
`
`Reckitt. But the Mucinex label does not claim that Mucinex DM is non-drowsy, because this is
`
`not the truth.
`
`
`8 How to read over the counter (OTC) drug labels, Consumer Reports,
`https://www.consumerreports.org/cro/2014/04/how-to-read-over-the-counter-drug-labels/index.htm
`9 https://www.merriam-webster.com/medical/nondrowsy
`
`6
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 9 of 19 PageID #:9
`
`
`
`26.
`
`So Defendants could have simply omitted the false and misleading statement,
`
`“Non-Drowsy,” from their products.
`
`27.
`
`Or, if Defendants wanted to say something to indicate that a Non-Drowsy
`
`Walgreens Product might cause less drowsiness than another product, they could have made a
`
`truthful statement to this effect, as other drug makers do.
`
`28.
`
`For example, Dramamine contains an active ingredient that causes drowsiness,
`
`Dimenhydrinate. Dramamine also sells a “less drowsy” version that contains a different active
`
`ingredient, Meclizine, which causes less drowsiness. The front label of Dramamine Less
`
`Drowsy prominently displays that it is “less drowsy”:
`
`
`
`
`
`
`
`
`
`
`
`7
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 10 of 19 PageID #:10
`
`
`
`29. Whether or not an over-the-counter drug causes drowsiness is material to a
`
`reasonable customer. In certain situations, consumers prefer over-the-counter drugs that will not
`
`make them drowsy to products that may make them drowsy. For example, all else equal, a
`
`reasonable consumer would prefer to take a drug that does not cause drowsiness to one that does
`
`cause drowsiness during the day (or any periods of time when they plan to be awake). As a
`
`second example, if a consumer is planning to engage in activities that require them to be alert
`
`(like work), or during which they would prefer to be alert, that consumer would prefer to take a
`
`drug that does not cause drowsiness to one that does. Indeed, in many situations, taking a drug
`
`that does or can cause drowsiness can be dangerous. For example, taking a drug that causes
`
`drowsiness while driving is dangerous.
`
`D.
`
`30.
`
`Plaintiff was misled by Defendants’ misrepresentations
`
`In or around 2019, Plaintiff bought a Non-Drowsy Walgreens Product (Wal-
`
`Tussin DM) at a Walgreens store in Bellingham, Washington. The package said “Non-Drowsy”
`
`prominently on the label, and Plaintiff read and relied on this statement when purchasing the
`
`8
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 11 of 19 PageID #:11
`
`product. But when Plaintiff took the Walgreens medication, she became unexpectedly drowsy.
`
`She would not have bought the Walgreens medication had she known that the product did, in
`
`fact, cause drowsiness, and that drowsiness was a known side-effect of the product.
`
`31.
`
`Plaintiff would purchase Non-Drowsy Walgreens Products again if they were
`
`actually “Non-Drowsy” (i.e., if the product was sold as advertised). Plaintiff, however, faces an
`
`imminent threat of harm because she will not be able to rely on the labels in the future, and thus
`
`will not be able to purchase the products.
`
`E.
`
`32.
`
`Class Action Allegations.
`
`Plaintiff brings certain claims on behalf of the proposed class of: all persons who
`
`purchased a Non-Drowsy Walgreens Product in the United States during the applicable statute of
`
`limitations (the “Nationwide Class”).
`
`33.
`
`For other claims, Plaintiff brings those claims on behalf of a subclass of
`
`consumers who live in the identified states (the “Consumer Protection Subclass”).
`
`34.
`
`For certain claims, Plaintiff brings those claims on behalf of a subclass of
`
`consumers who, like Plaintiff, purchased Non-Drowsy Walgreens Products in Washington (the
`
`“Washington Subclass”).
`
`35.
`
`The following people are excluded from the Class and the Subclasses: (1) any
`
`Judge or Magistrate Judge presiding over this action and the members of their family; (2)
`
`Defendants, Defendants’ subsidiaries, parents, successors, predecessors, and any entity in which
`
`the Defendants or their parents have a controlling interest and their current employees, officers
`
`and directors; (3) persons who properly execute and file a timely request for exclusion from the
`
`Class; (4) persons whose claims in this matter have been finally adjudicated on the merits or
`
`otherwise released; (5) Plaintiff’s counsel and Defendants’ counsel, and their experts and
`
`9
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 12 of 19 PageID #:12
`
`consultants; and (6) the legal representatives, successors, and assigns of any such excluded
`
`persons.
`
`Numerosity
`
`36.
`
`The proposed class contains members so numerous that separate joinder of each
`
`member of the class is impractical. Based on the pervasive distribution of Non-Drowsy
`
`Walgreens Products, there are millions of proposed class members.
`
`Commonality
`
`37.
`
`There are questions of law and fact common to the proposed class. Common
`
`questions of law and fact include, without limitation:
`
` Whether the Non-Drowsy Walgreens Products cause drowsiness;
`
` Whether Defendants’ labeling of the Non-Drowsy Walgreens Products as “Non-
`
`Drowsy” is deceptive and misleading;
`
` Whether Defendants violated state consumer protection statutes;
`
` Whether Defendants committed a breach of express warranty; and,
`
` Damages needed to reasonably compensate Plaintiff and the proposed class.
`
`Typicality
`
`38.
`
`Plaintiff’s claims are typical of the proposed class. Like the proposed class,
`
`Plaintiff purchased Non-Drowsy Walgreens Products.
`
`Predominance and Superiority
`
`39.
`
`The prosecution of separate actions by individual members of the proposed class
`
`would create a risk of inconsistent or varying adjudication with respect to individual members,
`
`which would establish incompatible standards for the parties opposing the class. For example,
`
`10
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 13 of 19 PageID #:13
`
`individual adjudication would create a risk that breach of the same express warranty is found for
`
`some proposed class members, but not others.
`
`40.
`
`Common questions of law and fact predominate over any questions affecting only
`
`individual members of the proposed class. These common legal and factual questions arise from
`
`central issues which do not vary from class member to class member, and which may be
`
`determined without reference to the individual circumstances of any particular class member.
`
`For example, a core liability question is common: whether Defendants’ “Non-Drowsy” labeling
`
`is false and misleading.
`
`41.
`
`A class action is superior to all other available methods for the fair and efficient
`
`adjudication of this litigation because individual litigation of each claim is impractical. It would
`
`be unduly burdensome to have individual litigation of millions of individual claims in separate
`
`lawsuits, every one of which would present the issues presented in this lawsuit.
`
`V.
`
`Claims.
`
`Count I: Violations of State Consumer Protection Acts
`(on behalf of Plaintiff and the Consumer Protection Subclass)
`
`Plaintiff incorporates by reference each and every factual allegation set forth
`
`42.
`
`above.
`
`43.
`
`This count is brought on behalf of Plaintiff and the Consumer Protection Subclass
`
`for violations of the following state consumer protection statutes:
`
`State
`New York
`Washington, D.C.
`Massachusetts
`Missouri
`
`Statute
`N.Y. Gen. Bus. Law § 349, and the following.
`D.C. Code § 28-3901, and the following.
`Mass. Gen Laws Ann. Ch. 93A, and the following.
`Mo. Rev. Stat. § 407, and the following.
`
`11
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 14 of 19 PageID #:14
`
`Rhode Island
`
`Vermont
`Washington
`
`R.I. Gen. Laws § 6-13.1- 5.2(B), and the
`following.
`9 V.S.A. § 2451, and the following.
`Wash. Rev. Code § 19.86.010, and the following.
`
`
`
`44.
`
`Each of these statutes is materially similar. Each broadly prohibits deceptive
`
`conduct in connection with the sale of goods to consumers. No state requires reliance, knowledge
`
`or intent. Instead, it is sufficient that the deceptive conduct is misleading to reasonable consumers
`
`and that the conduct proximately caused harm. See Allen v. ConAgra Foods, Inc., 331 F.R.D.
`
`641, 666 (N.D. Cal. 2019) (finding that these states can be grouped into a certifiable subclass).
`
`45.
`
`Defendants’ conduct, including the false labeling of the Non-Drowsy Walgreens
`
`Products and sale of those products to Plaintiff and class members, violates each statute’s
`
`prohibitions.
`
`46.
`
`The sale of Non-Drowsy Walgreens Products is the sale of goods to consumers.
`
`Hundreds of thousands (or potentially millions) of consumers purchase Non-Drowsy Walgreens
`
`Products.
`
`47.
`
`As alleged in detail above, Defendants’ misrepresentations were misleading to
`
`Plaintiff and to reasonable consumers.
`
`48.
`
`For Mass. Gen Laws Ann. Ch. 93A, Plaintiff mailed a notice and demand letter to
`
`Defendants’ headquarters on December 27, 2021. Upon the expiration of any governing statutory
`
`notice period, Plaintiff and the class seek all available injunctive or monetary relief.
`
`49.
`
`Plaintiff and class members were injured as a direct and proximate result of
`
`Defendants’ conduct, and this conduct was a substantial factor in causing them harm, because (a)
`
`they would not have purchased Non-Drowsy Walgreens Products if they had known that they
`
`12
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 15 of 19 PageID #:15
`
`cause drowsiness, or (b) they overpaid for the products because they are sold at a price premium
`
`due to Defendants’ misrepresentations.
`
`Count II: Violation of the Washington Consumer Protection Act, Wash. Rev. Code ch.
`19.86
`(on behalf of Plaintiff and the Washington Subclass)
`
`Plaintiff incorporates each and every factual allegation set forth above.
`
`50.
`
`51.
`
`Plaintiff brings this cause of action individually and for the Washington Subclass,
`
`seeking reasonable attorney fees, treble damages, and other relief.
`
`52.
`
`Plaintiff and the Subclass purchased Non-Drowsy Walgreens Products in
`
`Washington.
`
`53.
`
`Defendants’ false and misleading “Non-Drowsy” claims had the capacity to
`
`deceive a substantial portion of the public into believing that the Non-Drowsy Walgreens
`
`Products do not cause drowsiness.
`
`54.
`
`Defendants’ “Non-Drowsy” misrepresentations occurred in the conduct of trade or
`
`commerce affecting the people of the State of Washington.
`
`55.
`
`Defendants’ misrepresentations impact the public interest because they were
`
`committed in the course of the Defendants’ business, were committed repeatedly before the
`
`Plaintiff ever purchased a Non-Drowsy Walgreens Product, as part of a pattern of misrepresenting
`
`whether the Non-Drowsy Walgreens Products cause drowsiness, which affected hundreds of
`
`thousands (or potentially millions) of other Washington residents. Moreover, there is a substantial
`
`potential that Defendants’ wrongful conduct will continue into the future.
`
`56.
`
`Defendants’ “Non-Drowsy” misrepresentations were material. As alleged in detail
`
`above, these “Non-Drowsy” misrepresentations were important to consumers and affected their
`
`13
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 16 of 19 PageID #:16
`
`choice to purchase Non-Drowsy Walgreens Products. And, as alleged in detail above, these
`
`misrepresentations were likely to mislead reasonable consumers.
`
`57.
`
`Defendants’ misrepresentations were willful and knowing. Because Defendants
`
`make and sell the Non-Drowsy Walgreens Products, Defendants researched the known and
`
`common side effects of DXM. This is diligence that a large company like Walgreens would do
`
`when selling a drug. As a result, Defendants know that DXM causes drowsiness. Furthermore,
`
`Defendants control their labeling, knowingly put on the “Non-Drowsy” representations, and know
`
`the plain meaning of “Non-Drowsy.” Finally, it is standard practice in the industry to test labeling
`
`with consumers, and Defendants’ testing would confirm that “Non-Drowsy” is misleading.
`
`58.
`
`Plaintiff and Subclass members were injured as a direct and proximate result of
`
`Defendants’ conduct, and this conduct was a substantial factor in causing them harm, because
`
`they did not get what they paid for (cough syrup that was truthfully “Non-Drowsy”) and they
`
`overpaid for the products because the products are sold at a price premium due to Defendants’
`
`misrepresentations.
`
`59.
`
`Plaintiff and the Subclass seek treble damages, an injunction, reasonable attorney
`
`fees, expenses, and all other available relief. See Wash. Rev. Code ch. 19.86.090.
`
`Count III: Breach of Express Warranty
`(on behalf of Plaintiff and a Nationwide Class)
`
`Plaintiff incorporates by reference each and every factual allegation set forth
`
`Plaintiff brings this count individually and for the Nationwide Class.
`
`Defendants, as the designers, manufacturers, marketers, distributors, suppliers,
`
`above.
`
`60.
`
`61.
`
`62.
`
`and/or sellers of the Non-Drowsy Walgreens Products, issued material, written warranties by
`
`14
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 17 of 19 PageID #:17
`
`representing that the products were “Non-Drowsy.” This was an affirmation of fact about the
`
`products (i.e., a description of the effects of the ingredients) and a promise relating to the goods.
`
`63.
`
`This warranty was part of the basis of the bargain and Plaintiff and members of the
`
`Nationwide Class relied on this warranty.
`
`64.
`
`In fact, the Non-Drowsy Walgreens Products do not conform to the above-
`
`referenced representation because, as alleged in detail above, they cause drowsiness. Thus, the
`
`warranty was breached.
`
`65.
`
`Plaintiff provided Defendants with notice of this breach of warranty, by mailing a
`
`notice letter to Defendants’ headquarters, on December 27, 2021.
`
`66.
`
`Plaintiff and the Nationwide Class were injured as a direct and proximate result of
`
`Defendants’ breach, and this breach was a substantial factor in causing harm, because (a) they
`
`would not have purchased Non-Drowsy Walgreens Products if they had known that the products
`
`cause drowsiness, or (b) they overpaid for the products because they are sold at a price premium
`
`due to the warranty.
`
`Count IV: Breach of the Magnuson-Moss Warranty Act
`(on behalf of Plaintiff and the Nationwide Class)
`
`Plaintiff incorporates by reference each and every factual allegation set forth
`
`Plaintiff brings this count individually and for the Nationwide Class.
`
`Defendants supplied Non-Drowsy Walgreens Products to consumers and Non-
`
`above.
`
`67.
`
`68.
`
`69.
`
`Drowsy Walgreens Products are consumer products.
`
`70.
`
`Defendants issued material, written warranties by representing that the products
`
`were “Non-Drowsy.” This was an affirmation of fact about the material in the products (i.e., a
`
`description of the effects of the ingredients) and a promise relating to the goods.
`
`15
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 18 of 19 PageID #:18
`
`71.
`
`Defendants represented that the material inside the Non-Drowsy Walgreens
`
`Products (the ingredients) would meet a specified level of performance over a specified period of
`
`time. Defendants represented that, when taken at the recommended dosage, the product
`
`ingredients would not cause drowsiness and drowsiness is not a side-effect.
`
`72.
`
`This warranty was part of the basis of the bargain and Plaintiff and members of the
`
`Nationwide Class relied on this warranty.
`
`73.
`
`In fact, the Non-Drowsy Walgreens Products do not conform to the above-
`
`referenced representation because, as alleged in detail above, they cause drowsiness. Thus, the
`
`warranty was breached.
`
`74.
`
`Plaintiff provided Defendants with notice of this breach of warranty, by mailing a
`
`notice letter to Defendants’ headquarters, on December 27, 2021.
`
`75.
`
`Plaintiff and the Nationwide Class were injured as a direct and proximate result of
`
`Defendants’ breach, and this breach was a substantial factor in causing harm, because (a) they
`
`would not have purchased Non-Drowsy Walgreens Products if they had known that the products
`
`cause drowsiness, or (b) they overpaid for the products because the products are sold at a price
`
`premium due to the warranty.
`
`VI.
`
`Jury Demand.
`
`76.
`
`Plaintiff demands a jury trial on all issues so triable.
`
`VII. Prayer for Relief.
`
`77.
`
`Plaintiff seeks the following relief individually and for the proposed class and
`
`subclasses:
`
` An order certifying the asserted claims, or issues raised, as a class action;
`
` A judgment in favor of Plaintiff and the proposed class;
`
`16
`
`
`
`Case: 1:22-cv-00024 Document #: 1 Filed: 01/03/22 Page 19 of 19 PageID #:19
`
` Damages, treble damages, and punitive damages where applicable;
`
` Restitution;
`
` Disgorgement, and other just equitable relief;
`
` Pre- and post-judgment interest;
`
` An injunction prohibiting Defendants’ deceptive conduct, as allowed by law;
`
` Reasonable attorneys’ fees and costs, as allowed by law;
`
` Any additional relief that the Court deems reasonable and just.
`
`Date: January 3, 2022
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`By:
`
`
`
`
`
`/s/ Jonas Jacobson
`Jonas Jacobson
`
`DOVEL & LUNER, LLP
`Jonas Jacobson (pro hac vice forthcoming)
`Simon Franzini (pro hac vice forthcoming)
`201 Santa Monica Blvd., Suite 600
`Santa Monica, CA 90401
`(310) 656-7066
`jonas@dovel.com
`simon@dovel.com
`
`
`
`Counsel for Plaintiff
`
`
`
`17
`
`